• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

自毁型 CRISPR/Cas 构建物在视网膜靶向基因编辑中的效用。

Utility of Self-Destructing CRISPR/Cas Constructs for Targeted Gene Editing in the Retina.

机构信息

Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia.

Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, Australia.

出版信息

Hum Gene Ther. 2019 Nov;30(11):1349-1360. doi: 10.1089/hum.2019.021. Epub 2019 Oct 25.

DOI:10.1089/hum.2019.021
PMID:31373227
Abstract

Safe delivery of CRISPR/Cas endonucleases remains one of the major barriers to the widespread application of genome editing. We previously reported the utility of adeno-associated virus (AAV)-mediated CRISPR/Cas genome editing in the retina; however, with this type of viral delivery system, active endonucleases will remain in the retina for an extended period, making genotoxicity a significant consideration in clinical applications. To address this issue, we have designed a self-destructing "kamikaze" CRISPR/Cas system that disrupts the Cas enzyme itself following expression. Four guide RNAs (sgRNAs) were initially designed to target Cas9 (SpCas9) and after validation, the selected sgRNAs were cloned into a dual AAV vector. One construct was used to deliver SpCas9 and the other delivered sgRNAs directed against SpCas9 and the target locus (yellow fluorescent protein [YFP]), in the presence of mCherry. Both constructs were packaged into AAV2 vectors and intravitreally administered in C57BL/6 and transgenic mice. After 8 weeks, the expression of SpCas9 and the efficacy of gene disruption were quantified. A reduction of SpCas9 mRNA was found in retinas treated with AAV2-mediated YFP/SpCas9 targeting CRISPR/Cas compared with those treated with YFP targeting CRISPR/Cas alone. We also show that AAV2-mediated delivery of YFP/SpCas9 targeting CRISPR/Cas significantly reduced the number of YFP fluorescent cells among mCherry-expressing cells (∼85.5% reduction compared with LacZ/SpCas9 targeting CRISPR/Cas) in the transfected retina of transgenic mice. In conclusion, our data suggest that a self-destructive "kamikaze" CRISPR/Cas system can be used as a robust tool for genome editing in the retina, without compromising on-target efficiency.

摘要

CRISPR/Cas 内切酶的安全递送仍然是基因组编辑广泛应用的主要障碍之一。我们之前报道了腺相关病毒 (AAV) 介导的 CRISPR/Cas 基因组编辑在视网膜中的应用;然而,使用这种类型的病毒递送系统,活性内切酶将在视网膜中持续存在很长时间,使得基因毒性成为临床应用中的一个重要考虑因素。为了解决这个问题,我们设计了一种自毁的“神风”CRISPR/Cas 系统,在表达后会破坏 Cas 酶本身。最初设计了四个向导 RNA (sgRNA) 来靶向 Cas9 (SpCas9),经过验证后,选定的 sgRNA 被克隆到双 AAV 载体中。一个构建体用于递送 SpCas9,另一个构建体在 mCherry 的存在下递送靶向 SpCas9 和靶标 (黄色荧光蛋白 [YFP]) 的 sgRNA。这两个构建体都被包装到 AAV2 载体中,并通过玻璃体内注射给药于 C57BL/6 和转基因小鼠。8 周后,定量检测 SpCas9 的表达和基因敲除的效果。与单独用 YFP 靶向 CRISPR/Cas 处理的视网膜相比,用 AAV2 介导的 YFP/SpCas9 靶向 CRISPR/Cas 处理的视网膜中 SpCas9 mRNA 减少。我们还表明,AAV2 介导的 YFP/SpCas9 靶向 CRISPR/Cas 的递送显著减少了 mCherry 表达细胞中 YFP 荧光细胞的数量(与 LacZ/SpCas9 靶向 CRISPR/Cas 相比,减少了约 85.5%)在转染的转基因小鼠视网膜中。总之,我们的数据表明,自毁的“神风”CRISPR/Cas 系统可以作为一种强大的基因组编辑工具,用于视网膜,而不会影响靶点效率。

相似文献

1
Utility of Self-Destructing CRISPR/Cas Constructs for Targeted Gene Editing in the Retina.自毁型 CRISPR/Cas 构建物在视网膜靶向基因编辑中的效用。
Hum Gene Ther. 2019 Nov;30(11):1349-1360. doi: 10.1089/hum.2019.021. Epub 2019 Oct 25.
2
AAV-Mediated CRISPR/Cas Gene Editing of Retinal Cells In Vivo.体内视网膜细胞的腺相关病毒介导的CRISPR/Cas基因编辑
Invest Ophthalmol Vis Sci. 2016 Jun 1;57(7):3470-6. doi: 10.1167/iovs.16-19316.
3
Comparison of CRISPR/Cas Endonucleases for Retinal Gene Editing.用于视网膜基因编辑的CRISPR/Cas核酸内切酶的比较
Front Cell Neurosci. 2020 Sep 10;14:570917. doi: 10.3389/fncel.2020.570917. eCollection 2020.
4
Postnatal Cardiac Gene Editing Using CRISPR/Cas9 With AAV9-Mediated Delivery of Short Guide RNAs Results in Mosaic Gene Disruption.使用 CRISPR/Cas9 经 AAV9 介导的短向导 RNA 传递进行产后心脏基因编辑导致嵌合基因破坏。
Circ Res. 2017 Oct 27;121(10):1168-1181. doi: 10.1161/CIRCRESAHA.116.310370. Epub 2017 Aug 29.
5
Targeted Knockout of the Vegfa Gene in the Retina by Subretinal Injection of RNP Complexes Containing Cas9 Protein and Modified sgRNAs.通过含有 Cas9 蛋白和修饰 sgRNA 的 RNP 复合物的视网膜下注射靶向敲除视网膜中的 Vegfa 基因。
Mol Ther. 2021 Jan 6;29(1):191-207. doi: 10.1016/j.ymthe.2020.09.032. Epub 2020 Sep 23.
6
Use of AAV Vectors for CRISPR-Mediated In Vivo Genome Editing in the Retina.腺相关病毒载体在视网膜中用于CRISPR介导的体内基因组编辑
Methods Mol Biol. 2019;1950:123-139. doi: 10.1007/978-1-4939-9139-6_7.
7
Genome Editing with CRISPR-Cas9: Can It Get Any Better?使用CRISPR-Cas9进行基因组编辑:它还能更完善吗?
J Genet Genomics. 2016 May 20;43(5):239-50. doi: 10.1016/j.jgg.2016.04.008. Epub 2016 Apr 24.
8
Methods for In Vivo CRISPR/Cas Editing of the Adult Murine Retina.成年小鼠视网膜体内CRISPR/Cas编辑方法
Methods Mol Biol. 2018;1715:113-133. doi: 10.1007/978-1-4939-7522-8_9.
9
Carboxylated nanodiamond-mediated CRISPR-Cas9 delivery of human retinoschisis mutation into human iPSCs and mouse retina.羧基化纳米金刚石介导的 CRISPR-Cas9 递送人源视网膜劈裂症突变基因至人诱导多能干细胞和小鼠视网膜
Acta Biomater. 2020 Jan 1;101:484-494. doi: 10.1016/j.actbio.2019.10.037. Epub 2019 Oct 28.
10
Superior Fidelity and Distinct Editing Outcomes of SaCas9 Compared with SpCas9 in Genome Editing.SaCas9 与 SpCas9 在基因组编辑中的高保真度和明显的编辑效果比较。
Genomics Proteomics Bioinformatics. 2023 Dec;21(6):1206-1220. doi: 10.1016/j.gpb.2022.12.003. Epub 2022 Dec 20.

引用本文的文献

1
AAV-mediated gene therapies by miniature gene editing tools.通过微型基因编辑工具进行的腺相关病毒介导的基因治疗。
Sci China Life Sci. 2024 Dec;67(12):2540-2553. doi: 10.1007/s11427-023-2608-5. Epub 2024 Sep 27.
2
A promoterless AAV6.2FF-based lung gene editing platform for the correction of surfactant protein B deficiency.一种基于无启动子AAV6.2FF的肺基因编辑平台,用于纠正表面活性物质蛋白B缺乏症。
Mol Ther. 2023 Dec 6;31(12):3457-3477. doi: 10.1016/j.ymthe.2023.10.002. Epub 2023 Oct 7.
3
Current and Future Landscape in Genetic Therapies for Leber Hereditary Optic Neuropathy.
遗传性视神经病变的基因治疗的现状与未来。
Cells. 2023 Aug 7;12(15):2013. doi: 10.3390/cells12152013.
4
Advancements in pre-clinical development of gene editing-based therapies to treat inherited retinal diseases.基于基因编辑的治疗遗传性视网膜疾病的临床前开发进展。
Vision Res. 2023 Aug;209:108257. doi: 10.1016/j.visres.2023.108257. Epub 2023 May 19.
5
The application and progression of CRISPR/Cas9 technology in ophthalmological diseases.CRISPR/Cas9 技术在眼科疾病中的应用及进展。
Eye (Lond). 2023 Mar;37(4):607-617. doi: 10.1038/s41433-022-02169-1. Epub 2022 Aug 1.
6
Therapeutic in vivo delivery of gene editing agents.基因编辑试剂的治疗性体内递送。
Cell. 2022 Jul 21;185(15):2806-2827. doi: 10.1016/j.cell.2022.03.045. Epub 2022 Jul 6.
7
CRISPR-based VEGF suppression using paired guide RNAs for treatment of choroidal neovascularization.使用配对引导RNA基于CRISPR的血管内皮生长因子抑制用于治疗脉络膜新生血管。
Mol Ther Nucleic Acids. 2022 Apr 27;28:613-622. doi: 10.1016/j.omtn.2022.04.015. eCollection 2022 Jun 14.
8
New Editing Tools for Gene Therapy in Inherited Retinal Dystrophies.遗传性视网膜疾病的基因治疗新编辑工具。
CRISPR J. 2022 Jun;5(3):377-388. doi: 10.1089/crispr.2021.0141. Epub 2022 May 3.
9
Self-inactivating, all-in-one AAV vectors for precision Cas9 genome editing via homology-directed repair in vivo.通过体内同源定向修复实现精确 Cas9 基因组编辑的自失活、一体化 AAV 载体。
Nat Commun. 2021 Nov 1;12(1):6267. doi: 10.1038/s41467-021-26518-y.
10
CRISPR Technology for Ocular Angiogenesis.用于眼部血管生成的CRISPR技术
Front Genome Ed. 2020 Dec 22;2:594984. doi: 10.3389/fgeed.2020.594984. eCollection 2020.